More Insurance Claims Denials Are Being Overturned upon Appeal, Study Finds

Why It Matters

Rising appeal success rates expose weaknesses in insurers’ pre‑authorization systems, threatening patient access and prompting regulatory scrutiny.

Key Takeaways

• NY denial overturns rose from 38% to 53% (2019‑2025).
• Home‑health claim denials overturned >78% on appeal.
• Prescription and dental denials overturned just over 50% after appeal.
• Major insurers show 40‑50% overturn rates, some as low as 36%.
• Study limited to NY; national trends still unclear.

Pulse Analysis

The surge in claim‑denial appeals reflects a broader tension between insurers’ cost‑containment strategies and providers’ need for timely reimbursement. While prior authorizations are marketed as safeguards against waste, they often generate administrative bottlenecks that delay care and increase provider burnout. As AI‑driven algorithms scale up claim reviews, the margin for human error narrows, yet the data suggest many decisions are still being reversed, hinting at systemic calibration issues within underwriting platforms.

The New York analysis offers a granular look at how overturn rates vary by service line and insurer. Home‑health services, which frequently involve complex care coordination, saw the highest reversal rate—over three‑quarters of denials were overturned. In contrast, prescription‑drug and dental claims, which are more standardized, experienced roughly a 50% reversal rate. Insurers themselves displayed a wide spectrum: Metroplus’ 36% overturn rate sits at the low end, while Centers Plan for Healthy Living reached 85%. Such disparity underscores that internal policies, claim‑processing algorithms, and perhaps even contractual language shape outcomes as much as clinical merit.

Policymakers are watching these trends closely, especially after congressional attempts to curb prior‑authorization abuse stalled. The study’s authors argue that the growing volume of appeals and high reversal percentages signal a need for external oversight, potentially through standardized appeal pathways or stricter transparency mandates. For providers, the data reinforce the business case for investing in dedicated appeals teams, while patients gain leverage by knowing that a substantial share of denials are not final. As the industry grapples with balancing cost control and patient access, the next wave of reforms will likely focus on aligning algorithmic decision‑making with clinical reality, reducing unnecessary denials before they reach the appeal stage.